‘Validation of a MEK/MET-specific NGS panel for early phase trial interrogation‘ and ‘Upregulation of the MET transcript is consistently associated with invasion and tumor budding in colorectal cancer‘ were presented at the AACR Annual Meeting on 18 Apr 2016 in New Orleans. Mariangela Russo from UNITO also presented related work (Abstract 878). Validation of a MEK/MET-specific […]
This author has yet to write their bio.Meanwhile lets just say that we are proud mercuric contributed a whooping 58 entries.
Entries by mercuric
MErCuRIC partner hospital Hôpital Georges-Pompidou is hosting a Colorectal Cancer Information Day, open to the public on Tuesday 09 March. The event will include a simulation on the Da Vinci surgical robot and a Giant Colon to see what your own gut looks like! Registration is required at 01 56 09 39 82 or email@example.com
EUPATI (European Patients‘ Academy on Therapeutic Innovation) launched the EUPATI Toolbox today. Funded by the Innovative Medicines Initiative, EUPATI provides scientifically reliable, objective, comprehensive information to patients on medicines research and development. The Toolbox covers the A to Z of how medicines are developed. Check it out here!
MErCuRIC partners attended a successful meeting in Dublin, Ireland on 15 Jan 2016. Progress made by the consortium in year 2 was discussed and work for year 3 was planned. Our first Phase I study is drawing to a close and plans for the next Phase I work are well underway. We have also advanced the […]
MErCuRIC has been featured as a case study in the 2014- 2015 Annual Report of the Experimental Cancer Medicine Centre (ECMC) Network in the UK.
We’ve just launched a new patient area on the project website – have a look!
We’ve created a new area on the project website for publications from our partners that are relevant to MErCuRIC – check it out!
EUPATI, the European Patients’ Academy on Therapeutic Innovation has published their Oct 2015 newsletter – learn more about the experience of students who have just completed the first Patient Xpert Training Course and why regulatory agencies think patient education and engagement are important.
In an IFOM interview, MErCuRIC researcher Prof. Alberto Bardelli of the Universita Degli Studi di Torino talks about why he studies colorectal cancer. He describes personalised medicine, targeted therapies and resistance to therapy, as well as monitoring therapy in real time with blood-based assays called liquid biopsies. You can watch the interview here.
Educational videos from Cancer Research for Personalized Medicine (CARPEM) are now available online in French (English subtitles). Pr. Julien Taieb, gastrointestinal oncologist at the Georges Pompidou European Hospital (APHP), describes how advances in personalized medicine modify its practices in the treatment of digestive cancers.
MErCuRIC is funded by the European Community’s Framework Programme Seven (FP7) under contract #602901. The material presented and views expressed here are the responsibility of the author(s) only. The EU Commission takes no responsibility for any use made of the information set out.